Cytokinetics Inc (NASDAQ: CYTK) has reported a loss for its fourth fiscal quarter (ending December 31) of $-1.38 versus a loss $-1.45 for the same period a year ago. This result fell short of the consensus estimate of $-0.95 by $-0.43. For the latest four quarters through December 31, E.P.S. were $-5.45 versus $-4.33 for the same period a year ago.
Recent Price Action
Cytokinetics Inc (NASDAQ: CYTK) stock enjoyed a large increase of 2.5% on 2/27/24. The stock closed at $80.99. However, this advance was accompanied by unusually low trading volume at 56% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 5.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment